147 related articles for article (PubMed ID: 8389361)
21. Proteolytic cleavage of microtubule-associated proteins by retroviral proteinases.
Wallin M; Deinum J; Goobar L; Danielson UH
J Gen Virol; 1990 Sep; 71 ( Pt 9)():1985-91. PubMed ID: 2212989
[TBL] [Abstract][Full Text] [Related]
22. Continuous spectrophotometric assay for retroviral proteases of HIV-1 and AMV.
Nashed NT; Louis JM; Sayer JM; Wondrak EM; Mora PT; Oroszlan S; Jerina DM
Biochem Biophys Res Commun; 1989 Sep; 163(2):1079-85. PubMed ID: 2551268
[TBL] [Abstract][Full Text] [Related]
23. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.
Ridky TW; Kikonyogo A; Leis J; Gulnik S; Copeland T; Erickson J; Wlodawer A; Kurinov I; Harrison RW; Weber IT
Biochemistry; 1998 Sep; 37(39):13835-45. PubMed ID: 9753473
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases.
Weber IT
J Biol Chem; 1990 Jun; 265(18):10492-6. PubMed ID: 2162350
[TBL] [Abstract][Full Text] [Related]
25. Molecular model of equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions.
Weber IT; Tözsér J; Wu J; Friedman D; Oroszlan S
Biochemistry; 1993 Apr; 32(13):3354-62. PubMed ID: 8384880
[TBL] [Abstract][Full Text] [Related]
26. Molecular modeling of the HIV-1 protease and its substrate binding site.
Weber IT; Miller M; Jaskólski M; Leis J; Skalka AM; Wlodawer A
Science; 1989 Feb; 243(4893):928-31. PubMed ID: 2537531
[TBL] [Abstract][Full Text] [Related]
27. Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.
Grant SK; Deckman IC; Minnich MD; Culp J; Franklin S; Dreyer GB; Tomaszek TA; Debouck C; Meek TD
Biochemistry; 1991 Aug; 30(34):8424-34. PubMed ID: 1883829
[TBL] [Abstract][Full Text] [Related]
28. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.
Wlodawer A; Miller M; Jaskólski M; Sathyanarayana BK; Baldwin E; Weber IT; Selk LM; Clawson L; Schneider J; Kent SB
Science; 1989 Aug; 245(4918):616-21. PubMed ID: 2548279
[TBL] [Abstract][Full Text] [Related]
29. Specificity of the HIV-1 Protease on Substrates Representing the Cleavage Site in the Proximal Zinc-Finger of HIV-1 Nucleocapsid Protein.
Mótyán JA; Miczi M; Oroszlan S; Tőzsér J
Viruses; 2021 Jun; 13(6):. PubMed ID: 34201134
[TBL] [Abstract][Full Text] [Related]
30. Structural and biochemical studies of retroviral proteases.
Wlodawer A; Gustchina A
Biochim Biophys Acta; 2000 Mar; 1477(1-2):16-34. PubMed ID: 10708846
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of the substrate binding pocket of murine leukemia virus protease and comparison with human immunodeficiency virus proteases.
Menéndez-Arias L; Weber IT; Oroszlan S
J Biol Chem; 1995 Dec; 270(49):29162-8. PubMed ID: 7493942
[TBL] [Abstract][Full Text] [Related]
32. Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.
Eizert H; Bander P; Bagossi P; Sperka T; Miklóssy G; Boross P; Weber IT; Tözsér J
J Virol; 2008 Oct; 82(20):10111-7. PubMed ID: 18701588
[TBL] [Abstract][Full Text] [Related]
33. 15gag proteinase of myeloblastosis-associated virus: specificity studies with substrate-based inhibitors.
Pavlícková L; Stys D; Soucek M; Urban J; Hrusková O; Sedlácek J; Strop P
Arch Biochem Biophys; 1992 Nov; 298(2):753-6. PubMed ID: 1417001
[TBL] [Abstract][Full Text] [Related]
34. Processing, purification, and kinetic characterization of the Gag-Pol encoded retroviral proteinase of myeloblastosis associated virus expressed in E. coli.
Brynda J; Fábry M; Tichý PJ; Horejsí M; Sedlácek J
Adv Exp Med Biol; 1995; 362():485-8. PubMed ID: 8540362
[No Abstract] [Full Text] [Related]
35. Evaluation of homology modeling of HIV protease.
Weber IT
Proteins; 1990; 7(2):172-84. PubMed ID: 2158092
[TBL] [Abstract][Full Text] [Related]
36. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.
Konvalinka J; Litterst MA; Welker R; Kottler H; Rippmann F; Heuser AM; Kräusslich HG
J Virol; 1995 Nov; 69(11):7180-6. PubMed ID: 7474139
[TBL] [Abstract][Full Text] [Related]
37. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
38. Structural basis for specificity of retroviral proteases.
Wu J; Adomat JM; Ridky TW; Louis JM; Leis J; Harrison RW; Weber IT
Biochemistry; 1998 Mar; 37(13):4518-26. PubMed ID: 9521772
[TBL] [Abstract][Full Text] [Related]
39. Rous sarcoma virus integrase protein: mapping functions for catalysis and substrate binding.
Bushman FD; Wang B
J Virol; 1994 Apr; 68(4):2215-23. PubMed ID: 8139006
[TBL] [Abstract][Full Text] [Related]
40. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions.
Rosé JR; Salto R; Craik CS
J Biol Chem; 1993 Jun; 268(16):11939-45. PubMed ID: 8505318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
